Terrence O. Moore Retires as Chief Commercial Officer
SAN DIEGO--(BUSINESS WIRE)--Mar. 30, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced Michael J. Yang has joined ACADIA as
Executive Vice President and Chief Commercial Officer. Mr. Yang succeeds
Terrence O. Moore, who has served as ACADIA’s Chief Commercial Officer
since 2013, and is now retiring.
This Smart News Release features multimedia. View the full release here:
Michael J. Yang, Executive Vice President, Chief Commercial Officer (Photo: Business Wire)
“I am delighted to welcome Michael to our team,” said Steve Davis,
ACADIA’s President and Chief Executive Officer. “Michael is a seasoned
executive with extensive expertise in successfully launching and growing
major pharmaceutical products across a number of therapeutic areas,
including CNS. His patient-centric approach, proven leadership skills,
and focus on innovation will be of great value to the ongoing
commercialization of NUPLAZID in Parkinson’s disease psychosis and its
potential expansion into other areas of large unmet need.”
“Central nervous system disorders are one of the biggest challenges to
our healthcare system and severely impact the lives of both patients and
their families,” said Michael Yang. “As an innovative, first-in-class
product, NUPLAZID is transforming the treatment of patients suffering
from Parkinson’s disease psychosis. I look forward to building on the
success of NUPLAZID.”
“We thank Terry Moore for his significant contributions to ACADIA over
the past four years,” added Mr. Davis. “Under his leadership, we have
laid a strong foundation for the continued growth of NUPLAZID. We wish
him well in his retirement as he plans to move back to the East Coast
and spend more time with his family.”
Mr. Moore commented, “I am proud of what we have been able to achieve –
building the commercial foundation, launching NUPLAZID, and bringing
this novel drug to patients in need. After more than 30 years in the
life sciences industry, I’m pleased to hand the reins over to Michael to
lead the next phase of growth for ACADIA, and I look forward to watching
the company reach new levels of success.”
Mr. Yang joins ACADIA from Janssen Pharmaceutical Companies of Johnson &
Johnson, where he served as President of Janssen Biotech Inc. and was
responsible for building Janssen's U.S. Immunology business, generating
more than $8 billion in annual revenues. Mr. Yang began his career at
Johnson & Johnson in 1997 and held numerous senior commercial positions
such as President, CNS where he was responsible for growing the
anti-psychotic long-acting therapy portfolio. His broad background of
commercialization and general management experience also includes roles
as the Worldwide General Manager of the Medical Device companies of
Therakos, Inc and Veridex, LLC, where he launched new platforms,
expanded global revenues and diversified the product lines. Prior to
that, Mr. Yang was Vice President of Sales and Marketing, Oncology at
Ortho Biotech Inc.
Mr. Yang earned his Bachelor of Science degree in Business
Administration, Marketing from San Diego State University. Mr. Yang will
serve as a member of ACADIA’s executive team and report to Mr. Davis,
About NUPLAZID® (pimavanserin)
NUPLAZID is the first and only FDA-approved treatment for hallucinations
and delusions associated with Parkinson’s disease (PD) psychosis.
NUPLAZID is a non-dopaminergic, selective serotonin inverse agonist
preferentially targeting 5-HT2A receptors that are thought to
play an important role in PD Psychosis. NUPLAZID is an oral medicine
taken once a day with a recommended dose of 34 mg (two 17-mg tablets).
ACADIA discovered this new chemical entity and holds worldwide rights to
develop and commercialize NUPLAZID.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to the benefits to be derived from
NUPLAZID (pimavanserin); the utility or expansion of pimavanserin in
indications other than hallucinations and delusions associated with PD
Psychosis; and any future growth or success of NUPLAZID or ACADIA. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties. Actual
events or results may differ materially from those projected in any of
such statements due to various factors, including the risks and
uncertainties inherent in drug discovery, development, and
commercialization, and the fact that past results of clinical trials may
not be indicative of future trial results. For a discussion of these and
other factors, please refer to ACADIA’s annual report on Form 10-K for
the year ended December 31, 2016 as well as ACADIA’s subsequent filings
with the Securities and Exchange Commission. You are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date hereof. This caution is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise or
update this press release to reflect events or circumstances after the
date hereof, except as required by law.
Important Safety Information and Indication for
NUPLAZID (pimavanserin) tablets
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH
Elderly patients with
dementia-related psychosis treated with antipsychotic drugs are at an
increased risk of death. NUPLAZID is not approved for the treatment of
patients with dementia-related psychosis unrelated to the hallucinations
and delusions associated with Parkinson’s disease psychosis.
NUPLAZID is an atypical antipsychotic indicated for the treatment of
hallucinations and delusions associated with Parkinson’s disease
QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of
NUPLAZID should be avoided in patients with known QT prolongation or in
combination with other drugs known to prolong QT interval including
Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain
antipsychotic medications, and certain antibiotics. NUPLAZID should also
be avoided in patients with a history of cardiac arrhythmias, as well as
other circumstances that may increase the risk of the occurrence of
torsade de pointes and/or sudden death, including symptomatic
bradycardia, hypokalemia or hypomagnesemia, and presence of congenital
prolongation of the QT interval.
Adverse Reactions: The most common adverse reactions (≥2%
for NUPLAZID and greater than placebo) were peripheral edema (7%
vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination
(5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
Drug Interactions: Strong CYP3A4 inhibitors (eg, ketoconazole)
increase NUPLAZID concentrations. Reduce the NUPLAZID dose by one-half.
Strong CYP3A4 inducers may reduce NUPLAZID exposure, monitor for reduced
efficacy. Increase in NUPLAZID dosage may be needed.
Renal Impairment: No dosage adjustment for NUPLAZID is needed in
patients with mild to moderate renal impairment. Use of NUPLAZID is not
recommended in patients with severe renal impairment.
Hepatic Impairment: Use of NUPLAZID is not recommended in patients with
hepatic impairment. NUPLAZID has not been evaluated in this patient
Pregnancy: Use of NUPLAZID in pregnant women has not been evaluated and
should therefore be used in pregnancy only if the potential benefit
justifies the potential risk to the mother and fetus.
Pediatric Use: Safety and efficacy have not been established in
Dosage and Administration: Recommended dose: 34 mg per day, taken orally
as two 17-mg tablets once daily, without titration.
For additional Important Safety Information, including boxed warning,
please see the full Prescribing Information for NUPLAZID at https://www.nuplazid.com/pdf/NUPLAZID_Prescribing_Information.pdf.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170330005419/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.